REFERENCES:
1.Sokeng, S.D., D. Lontsi, P.F. Moundipa, H.B. Jatsa, P. Watcho and P. Kamtchouing, 2007. Hypoglycemic Effect of AnacardiumoccidentaleL.Methanol Extract and Fractions on Streptozotocin-induced Diabetic Rats. Global Journal of Pharmacology, 1(1): 01-05.
2.Baquer, N.Z., D. Gupta and J. Raju, 1998. Regulation of metabolic pathways in liver and kidney during experimental diabetes. Effects of antidiabetic compounds. Indian J Clinical Biochem, 13: 63-80.
3. Visweswara Rao, P. and M. Dhananjaya Naidu, 2010. Anti Diabetic Effect of Rhinacanthusnasutus Leaf Extract in Streptozotocin Induced Diabetic Rats. Libyan Agriculture Research Center Journal International, 1(5): 310-312.
4.Grijesh Kumar Mall, PankajKishor Mishra and Veeru Prakash, 2009. Antidiabetic and Hypolipidemic Activity of Gymnemasylvestre in Alloxan Induced Diabetic Rats. Global Journal of Biotechnology and Biochemistry, 4(1): 37-42.
5.Baquer, N.Z., D. Gupta and J. Raju, 1998. Regulation of metabolic pathways in liver and kidney during experimental diabetes. Effects of antidiabetic compounds. Indian J. Clinical Biochem, 13: 63-80.
6. EilyadIssabeagloo, Reza forughi, Mohammed Taghizadieh and ParvizKermanizadeh, 2012. Effect of Alcohol on Blood Glucose Levels in Streptozotocin Induced Diabetic Rats. Middle-East Journal of Scientific Research, 12(3): 290-293.
7. Mohammad Yaheya Mohammad Ismail, 2009. Clinical Evaluation of Antidiabetic Activity of Trigonella Seeds and Aeglemarmelos Leaves, World Applied Sciences Journal, 7(10): 1231-1234.
8. NisarZamin Shah, Naveed Muhammad, SadiaAzeem and AbdurRauf, 2013.Hypoglycemic Effect of Crude Methanolic Extract as Well as Sub Fractions of Morusalba on Rabbits. Global Journal of Pharmacology, 7(1): 91-94.
9. International Diabetes Federation. The IDF Diabetes Atlas. Fifth Edition. Brussels: International Diabetes Federation, 2011.
10. Chao, E.C. and R.R. Henry, 2010. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat. Rev. Drug. Discov, 9: 551-559.
11. ManmohanSinghal, ShaileeRasania, Amit Gaur, Manchireddy Vishnu, V.R. Vijaya Rama Raju and S. YozanaUpadhyay, 2012. Overview on Sodium Glucose Transport Inhibitors as a Therapeutic Tool against Diabetes Mellitus. Global Journal of Pharmacology, 6(2): 86-93.
12. Lambeir, A.M., C. Durinx, Scharpe and S. De Meester, 2003. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci., 40: 209-294.
13. Wu, X.D., H.J. Deeb, R. Singh and N. Sedkova, 2001. Depot-Specific Variation in Protein-Tyrosine phosphatase activities in human mentaland Subcutaneous adipose tissue: A Potential Contribution to Differential Insulin Sensitivity. J. ClinEndocrinolMetab, 86: 5973-5980.
14. Susie Chang, Marjorie J. Rosenberg, Holmes Morton, Clair A. Francomano and Leslie G. Biesecker, 1998. Identification of a mutation in liver glycogen phosphorylase in glycogen storage disease type VI. Hum Mol Genet, 7: 142-145.
15. Basu, R., A. Basu, C.M. Johnson, W.F. Schwenk and R.A. Rizza, 2004. Insulin dose response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in non-diabetic humans and are abnormal in people with type 2 diabetes mellitus. Diabetes, 53: 2042-2050.
16. Pearson, S.L., M.A. Cawthorne, J.C. Clapham, S.J. Dunmore, S.D. Holmes, G.B. Moore, S.A. Smith and M. Tadayyon, 1996. The thiazolidinedione insulin sensitiser, BRL 49653, increases the expression of PPAR-gamma and aP2 in adipose tissue of high-fat-fed rats. BiochemBiophys Res Commun, 229(3): 752-757.
17.Istvan, E.S., M. Palnitkar, S.K. Buchanan and J. Deisenhofer, 2000. Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis. EMBO J, 19: 819- 830.
18. Abbott CA, Yu DMT, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem. 2000; 67: 6140-50.
19. Weber AE. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem. 2004; 47: 4135-41.
20. Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005; 48: 616-20.
21. Fredenrich A, Palle S, Canivet B. Dipeptidyl peptidase inhibitors: A new step towards normoglycemia. Open
Endocrinol J. 2009; 3: 16-21.
22. Biftu, T., G. Scapin, S. Singh, D. Feng, J.B. Becker, G. Eiermann, H. He, K. Lyons, S. Patel, A. Petrov, R. Sinha-Roy, B. Zhang, J. Wu, X. Zhang, G.A. Doss, N.A. Thornberry and A.E. Weber, 2007. (3R)-4-[(3R)- 3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2- trifluoroethyl)-1,4-diazepan-2-one,a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg. Med ChemLett, 17: 49-52.
23. Trott O & Olson AJ, J Comput Chem. 2010; 31(2): 455-61